a hrefhttps:www.fiercepharma.compharmascholar-rock-ditches-novo-legacy-catalent-plant-fda-refiling-sma-drug hreflangenScholar Rock ditches Novos legacy Catalent plant in FDA refiling of SMA druga

Scholar Rock has dropped Novo Nordisks troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of the plant was classified as Official Action Indicated.